NCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
Pfizer
Pierre Fabre Medicament
Intergroupe Francophone de Cancerologie Thoracique
Pfizer
Pfizer
Eli Lilly and Company
Array BioPharma